IN8bio, Inc. INAB 深 沪
等待开盘 02-05 09:30:00 美东时间
1.96
-0.030
-1.51%
华盛通- 最 高2.14
- 今 开2.02
- 成交量 3.00万股
- 最 低 1.95
- 昨 收 1.99
- 总市值 889.78万
- 52周最高 9.00
- 市盈率 静 --
- 换手率 0.66%
- 52周最低 1.17
- 委 比 46.18%
- 总股本 453.97万
- 历史最高 309.57
- 量 比 0.54
- 振 幅 9.55%
- 历史最低 1.87
- 每 手 1
- 风险率 2.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Clene (NASDAQ:CLNN) stock increased by 10.0% to $7.94 during Wednesday'...
2025-12-04 05:06
IN8bio Presents Consolidated INB-200 Phase 1 And INB-400 Phase 2 Glioblastoma Data At 2025 SNO Annual Meeting
IN8bio, Inc. (the "Company") presented consolidated data, a summary of which is located below, from its investigator-sponsored Phase 1 single-center clinical trial of INB-200 and its Company-sponsored Phase 2
2025-11-25 03:53
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
IN8bio, Inc. announced the addition of The Ohio State University as a new clinical site in its Phase 1 trial for INB-100, a donor-derived allogeneic gamma-delta T cell therapy for patients with leukemias undergoing haploidentical stem cell transplantation. This expansion aims to accelerate enrollment and evaluate INB-100's safety, durability, and anti-leukemic activity post-transplant, with promising long-term remission data already observed.
2025-10-29 12:00
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
INB-619 demonstrated equivalent efficacy to FDA-approved T Cell Engagers (TCE) for B cell depletion with minimal cytokine release, highlighting safer deep B cell depletion. It is the first pan-gamma delta T cell engager designed to expand multiple gamma delta T cell subsets for efficient target elimination. INB-619 achieved robust gamma delta T cell expansion and complete B cell depletion in both healthy donor and SLE samples. Unlike conventional...
2025-10-27 12:00
IN8bio Q2 EPS $(1.24) Beats $(1.70) Estimate
IN8bio (NASDAQ:INAB) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.70) by 27.06 percent. This is a 78.25 percent increase over losses of $(5.70) per share from the same
2025-08-08 04:08
IN8bio Regains Nasdaq Compliance with Bid Price Rule
An update from IN8bio ( ($INAB) ) is now available. On June 24, 2025, IN8bio, I...
2025-07-01 02:48
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
IN8bio announced that Patient 009 with grade 4 IDH-mutant glioma treated with INB-200 gamma-delta T cell therapy has achieved 4 years progression-free survival. This outcome surpasses typical results for IDH-mutant glioma patients and highlights the potential of gamma-delta T cell therapy for treating aggressive cancers. INB-200 demonstrated extended mPFS of 16.1 months in Phase 1 trial, exceeding the standard-of-care Stupp protocol's 6.9 months....
2025-06-09 11:00
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
IN8bio announced new data from its Phase 1 trial of INB-200 for newly diagnosed glioblastoma multiforme (GBM). The treatment showed a median progression-free survival (mPFS) of 16.1 months, more than doubling the historical 6.9 months under the standard-of-care Stupp protocol. Four patients remained alive and progression-free for over two years, with no serious toxicities beyond typical chemotherapy side effects. The improved mPFS surpasses the h...
2025-06-02 11:30
IN8bio Wins ISCT Abstract Award For Analytical Characterization Of Its Gamma-Delta T Cell Therapies In INB-100 AML Trial, Demonstrating Durable Relapse-Free Survival And Showcasing Consistent, Potent Anti-Cancer Activity Through Its Proprietary DeltEx Allo Manufacturing Platform
Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML
2025-05-12 20:09
快讯 | In8bio发布2025年第一季度财务报告及近期业务亮点
IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlig...
2025-05-08 04:00
